Stockscreener 앱 받기
1.43
1.38%
-0.02
시간 외 거래:
1.45
0.02
+1.40%
전일 마감가:
$1.45
열려 있는:
$1.42
하루 거래량:
125.64K
Relative Volume:
0.57
시가총액:
$44.61M
수익:
$81,000
순이익/손실:
$-41.04M
주가수익비율:
-1.0859
EPS:
-1.3169
순현금흐름:
$-30.69M
1주 성능:
+1.42%
1개월 성능:
+0.00%
6개월 성능:
-0.69%
1년 성능:
+0.00%
1일 변동 폭
$1.402
$1.49
1주일 범위
$1.33
$1.49
52주 변동 폭
$1.06
$2.41
Actinium Pharmaceuticals Inc Stock (ATNM) Company Profile
명칭
Actinium Pharmaceuticals Inc
전화
646-767-3870
주소
275 Madison Avenue, 7th Floor, New York, NY
ATNM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ATNM
Actinium Pharmaceuticals Inc
|
1.43 | 45.23M | 81,000 | -41.04M | -30.69M | -1.3169 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Actinium Pharmaceuticals Inc Stock (ATNM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-07 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2024-05-14 | 개시 | Stephens | Overweight |
| 2023-09-06 | 개시 | HSBC Securities | Buy |
| 2023-02-21 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2022-09-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-08-25 | 개시 | B. Riley Securities | Buy |
| 2020-11-05 | 개시 | Alliance Global Partners | Buy |
| 2017-12-06 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-10-23 | 재개 | ROTH Capital | Buy |
| 2017-09-14 | 개시 | Maxim Group | Buy |
| 2016-08-25 | 개시 | ROTH Capital | Buy |
| 2016-02-29 | 개시 | H.C. Wainwright | Buy |
| 2015-10-15 | 개시 | FBR Capital | Outperform |
| 2014-10-01 | 개시 | MLV & Co | Buy |
| 2014-07-22 | 개시 | Canaccord Genuity | Buy |
모두보기
Actinium Pharmaceuticals Inc 주식(ATNM)의 최신 뉴스
Are Medical Stocks Lagging Actinium Pharmaceuticals (ATNM) This Year? - Yahoo Finance
Published on: 2025-12-20 18:07:18 - Улправда
Will Actinium Pharmaceuticals Inc. stock benefit from upcoming earnings reportsForecast Cut & Short-Term High Return Ideas - Улправда
Will Actinium Pharmaceuticals Inc. stock outperform value stocksJuly 2025 Patterns & Growth Oriented Trade Recommendations - Улправда
AstraZeneca’s Long-Term Isotope Deal Validates Actinium Pharmaceuticals’ Core Technology - AD HOC NEWS
Can Actinium Pharmaceuticals Inc. stock continue upward trendEarnings Growth Report & Expert Curated Trade Setups - Улправда
Will Actinium Pharmaceuticals Inc. stock outperform Dow Jones index2025 Growth vs Value & Reliable Breakout Stock Forecasts - Улправда
How Actinium Pharmaceuticals Inc. (Delaware) stock responds to job market shiftsJuly 2025 Closing Moves & High Accuracy Buy Signal Tips - Улправда
Can Actinium Pharmaceuticals Inc. stock hit analyst price targetsJuly 2025 Catalysts & Consistent Profit Trade Alerts - DonanımHaber
Aug Intraday: Can Actinium Pharmaceuticals Inc. stock continue upward trendJuly 2025 Big Picture & Safe Capital Investment Plans - Улправда
Is Actinium Pharmaceuticals Inc. stock a top pick in earnings seasonJuly 2025 PostEarnings & Growth Oriented Trade Recommendations - Улправда
Published on: 2025-12-18 21:38:16 - Улправда
Can Actinium Pharmaceuticals Inc. (Delaware) stock sustain revenue momentumInsider Buying & AI Forecasted Stock Moves - Улправда
Actinium Pharmaceuticals stock rises after promising breast cancer therapy data - Investing.com Australia
Why Is Actinium Pharmaceuticals Stock Rising Today? - Menafn.com
Why is Actinium Pharmaceuticals stock rising today? - MSN
Actinium (ATNM) Reveals Promising Preclinical Data for Novel Can - GuruFocus
Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Br - PR Newswire
Actinium Pharmaceuticals Advances Trop-2 Targeted Alpha Radiotherapy Into Phase 1/2 Trials in the U.S. and Australia - openPR.com
Actinium Pharmaceuticals (NYSE:ATNM) Stock Price Down 0.7% – Here’s Why - Defense World
Actinium Pharmaceuticals (NYSEAMERICAN: ATNM) Begins - openPR.com
Actinium Pharmaceuticals: Clinical Milestone and Promising Data Fuel Oncology Pipeline - AD HOC NEWS
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) Advances - openPR.com
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) Advances ATNM-400 Targeting STEAP-1 Across Prostate, Breast, and Lung Cancer - marketscreener.com
ATNM-400 Targets B7-H3 and Is Being Studied in a Phase 1 Clinical Trial in South Africa - openPR.com
Actinium Pharmaceuticals Advances ATNM-400 B7-H3 Candidate Into Phase 1 Clinical Trial in South Africa - openPR.com
Can Actinium Pharmaceuticals Inc. (7AY1) stock double in coming yearsJuly 2025 Opening Moves & Safe Entry Point Alerts - Newser
Will Actinium Pharmaceuticals Inc. (Delaware) stock gain from lower interest ratesJuly 2025 Highlights & Risk Controlled Stock Alerts - Newser
Why analysts recommend Actinium Pharmaceuticals Inc. (Delaware) stock2025 Earnings Surprises & Daily Entry Point Trade Alerts - Newser
How Actinium Pharmaceuticals Inc. (Delaware) stock expands through international markets2025 Short Interest & Real-Time Chart Pattern Alerts - Newser
Will Actinium Pharmaceuticals Inc. (Delaware) stock beat Nasdaq index returnsChart Signals & Consistent Profit Alerts - Newser
Why hedge funds are buying Actinium Pharmaceuticals Inc. stockMarket Activity Report & Real-Time Volume Spike Alerts - Newser
Is Actinium Pharmaceuticals Inc. (7AY1) stock a momentum leaderJuly 2025 Volume & Fast Gain Swing Trade Alerts - Newser
Why Actinium Pharmaceuticals Inc. stock is a value investor pick2025 Market WrapUp & Expert Approved Trade Ideas - Newser
Jeri Kim: Thrilled to Join Actinium Pharmaceuticals as VP, Head of Solid Tumor Clinical Development - Oncodaily
Will Actinium Pharmaceuticals Inc. stock benefit from green energy trendsJobs Report & Daily Entry Point Alerts - Newser
Why retail traders accumulate Actinium Pharmaceuticals Inc. (Delaware) stockJuly 2025 Review & Real-Time Chart Breakout Alerts - Newser
How Actinium Pharmaceuticals Inc. (7AY1) stock valuation compares with sectorQuarterly Portfolio Summary & Weekly High Potential Alerts - Newser
How cyclical is Actinium Pharmaceuticals Inc. (7AY1) stock compared to rivalsJuly 2025 Volume & Smart Investment Allocation Insights - Newser
Actinium’s ATNM-400 shows efficacy in resistant breast cancers By Investing.com - Investing.com Australia
Actinium Pharmaceuticals (ATNM) Unveils Promising Preclinical Da - GuruFocus
Actinium's ATNM-400 shows strong efficacy in TNBC, beats therapy resistance at SABCS - marketscreener.com
Actinium Pharmaceuticals Inc (ATNM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.52%
0.07%
자본화:
|
볼륨(24시간):